Lowering blood pressure and cholesterol to improve kidney health in advanced chronic kidney disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to prevent the progression of kidney disease in adults with advanced chronic kidney disease by implementing intensive control of blood pressure and lipid levels. It utilizes a 2X2 factorial design to compare the effects of intensive versus standard blood pressure control and intensive versus standard lipid management. Approximately 642 participants aged 19 and older with specific criteria will be enrolled and followed for three years to assess kidney disease progression. The study is conducted across 13 clinics over a two-year recruitment period.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Fulfillment of all of followings

  1. At least 19 years old
  2. Evidence of CKD defined at least 3 months before and at the time of screening visit with CKD-EPI eGFR ≥15 to \<45 mL/min/1.73 m2
  3. SBP of

     * 130-180 mmHg on 0 or 1 medication
     * 130-170 mmHg on upto 2 medications
     * 130-160 mmHg on more than 3 medications
  4. LDL-C ≥100 mg/dL

Exclusion Criteria:

* Any of followings

  1. Resistant hypertension or poorly controlled hypertension

     * Failure to achieve SBP of \<140 mmHg despite using 4 or more antihypertensive medications including diuretics
  2. Known secondary cause of hypertension
  3. History of renal devervation procedure
  4. Glomerulonephritis requiring immunosuppresive agents
  5. Autosomal dominant polycystic kidney disease receiving tolvaptan
  6. CKD-EPI \< 15 mL/min/1.73 m2 or receiving kidney replacement therapy
  7. Familial hypercholesterolemia
  8. Cardiovascular event or precedure (as defined as myocardial infarction, unstable angina, coronary revascularization, or stroke) within last 3 months or planning to cardiovascular procedure upcoming 3 months at the time of screening visit
  9. Symptomatic heart failure within 6 months of left ventricular ejection fraction \<45%
  10. A medical condition likely to limit survival to less thant 3 years
  11. Diagnosis of malignancy within the last 5 years or undergoing chemotherepy or radiotherapy
  12. Any organ transplant
  13. Advanced cirrhosis (Child-Pugh class B or C) or abnormal liver function test (alanine transaminase or aspartate transaminase ≥1.5 X upper normal limit)
  14. Evidence of active inflammatory muscle disease (polymyositis or dermatomyositis) or creatine kinase elevation (≥3 X upper normal limit)
  15. History of adverse reaction to HMG-CoA reductase inhibitors or ezetimibe
  16. Using any drugs as followings:

      * Nicotinic acid
      * Macrolide antibiotics
      * Systemic imidazole or triazole antifungal agent
      * Protease inhibitor
      * Nefazodone
      * Immunosuppressive agents (glucocorticoid \[equivalent to prednisone 10 mg/day over 4 weeks\], cyclosporin, mycofenolate, azathioprine, methotrexate, cyclophosphamide, or rituximab)
  17. Pregnancy or trying to become pregnant
  18. Diabetes mellitus, type I
  19. Diabetes mellitus, type II with HbA1c ≥10.0%

Where it's running

• Severance Hospital
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Seung Hyeok Han
• Email: hansh@yuhs.ac
• Phone: 82-2-2228-1984

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Home-based cardiovascular health screening for people turning 50, 55, 60, 65, 70 or 75 in Uppsala

  This trial tests whether giving people a home blood pressure monitor, a dried blood spot kit, and a questionnaire can find more cardiovascular risk factors than usual care.

  Recruiting Uppsala University · Uppsala · NCT07614659

• Taining Golden Lake comprehensive chronic disease management program

  This project will build a large cohort of adults in Taining County to collect health data and try to create a county-level chronic disease management model for people with hypertension, diabetes, dyslipidemia, and other long-term conditions.

  Recruiting First Affiliated Hospital of Fujian Medical University · Fuzhou, Fujian · NCT07308314

• Streamlined renal denervation with Spyral for uncontrolled high blood pressure

  This trial will test whether a shorter, simpler renal denervation procedure using the Symplicity Spyral system can lower blood pressure in adults with uncontrolled hypertension.

  Recruiting at 20 sites Medtronic Vascular · Melbourne and 20 other locations · NCT07115953

• Gemini multi-organ denervation for uncontrolled high blood pressure

  The Gemini System is being tested to see if multi-organ denervation is safe and can lower blood pressure in adults with uncontrolled hypertension, with or without high cardiovascular risk.

  Recruiting at 18 sites Medtronic Vascular · Stanford, California and 17 other locations · NCT06907147

• Cooking demonstrations to improve health in Native Hawaiians

  This study is trying out cooking demonstrations to help Native Hawaiians manage heart and diabetes-related health issues by promoting traditional diets and healthier eating habits.

  Recruiting at 2 sites University of Hawaii · Honolulu, Hawaii and 1 other locations · NCT06526650

• Improving health in Native Hawaiians through traditional diets and cooking

  This study is testing if a program that promotes traditional Hawaiian diets and cooking can help Native Hawaiians with diet-related health issues improve their eating habits and overall health.

  Recruiting at 2 sites University of Hawaii · Honolulu, Hawaii and 1 other locations · NCT06526273

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.